RBC Capital Downgrades Iterum Therapeutics (ITRM) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ITRM Hot Sheet
Price: $0.03 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
RBC Capital analyst Gregory Renza downgraded Iterum Therapeutics (NASDAQ: ITRM) from Outperform to Sector Perform with a price target of $2.00 (from $7.00).
For an analyst ratings summary and ratings history on Iterum Therapeutics click here. For more ratings news on Iterum Therapeutics click here.
Shares of Iterum Therapeutics closed at $1.86 yesterday.
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,235 at Axis Capital Limited
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
